Herceptin copycat arrives
China’s National Medical Products Administration has approved the country’s first biosimilar for Herceptin, Roche’s blockbuster cancer therapy.
Shanghai Henlius Biotech announced last week that its trastuzumab biosimilar, HLX02, is now approved in China to treat patients with HER2-positive breast cancer and HER2-positive metastatic gastric cancer, making it the first Chinese-developed monoclonal antibody biosimilar to be approved in both China and the EU.
The arrival of HLX02 is a blow to Roche’s Herceptin. In its latest quarterly update, the Swiss drug maker said its overall product sales have been impacted by increasing competition from biosimilars and the impact of Covid-19. Growth in China was also partially offset by China’s National Drug Reimbursement List price cuts, the company said.
Shanghai Henlius Biotech announced last week that its trastuzumab biosimilar, HLX02, is now approved in China to treat patients with HER2-positive breast cancer and HER2-positive metastatic gastric cancer, making it the first Chinese-developed monoclonal antibody biosimilar to be approved in both China and the EU.
The arrival of HLX02 is a blow to Roche’s Herceptin. In its latest quarterly update, the Swiss drug maker said its overall product sales have been impacted by increasing competition from biosimilars and the impact of Covid-19. Growth in China was also partially offset by China’s National Drug Reimbursement List price cuts, the company said.
.png)
No hay comentarios:
Publicar un comentario